Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.50 |
| ▸ | CTSS | P25774 | 6/20 | 0.50 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646750 | 1.00 | CTSK (0.50) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL206031 | 1.00 | CTSK (0.50) | CTSKCTSSPPARAPPARGCTSL | |
| Hydrochloric Acid SCHEMBL16235893 | 0.98 | CTSK (0.49) | CTSKCTSSPPARAPPARGCTSL | |
| Hydrochloric Acid SCHEMBL14471562 | 0.98 | CTSK (0.49) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL303955 | 0.86 | CTSK (0.49) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL303956 | 0.86 | CTSK (0.49) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL2612149 | 0.86 | CTSK (0.49) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL25256775 | 0.85 | CYP1A2 (0.47) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL20783244 | 0.85 | CYP1A2 (0.47) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL2393366 | 0.85 | CYP1A2 (0.47) | CTSKCTSSCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119751411-A | Aggregation-induced emission probe design, synthesis and sterilization application based on bioorthogonal reaction metabolism anchoring living bacteria strategy | 华南农业大学 | 2025-04-04 | — | — | CN | claimed |
| EP-3828163-B1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME | AUTOTAC INC (KR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4656638-A2 | PYRAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-12-03 | — | — | EP | disclosed |
| WO-2025235389-A1 | P53 MODULATORS | NESTED THERAPEUTICS, INC. (US) | 2025-11-13 | — | — | WO | disclosed |
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | AUTOTAC INC. (KR) | 2025-09-30 | — | — | US | disclosed |
| WO-2025132943-A1 | DECAHYDROQUINOLINES AS DNA POLYMERASE THETA INHIBITORS | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025108986-A1 | 2-AMINO-N-(OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE | Oxford Drug Design Limited (GB) | 2025-05-30 | — | — | WO | disclosed |
| CN-119751411-A | Aggregation-induced emission probe design, synthesis and sterilization application based on bioorthogonal reaction metabolism anchoring living bacteria strategy | 华南农业大学 | 2025-04-04 | — | — | CN | disclosed |
| US-12178842-B2 | PCSK9 antagonist compounds | MERCK SHARP & DOHME LLC (US) | 2024-12-31 | — | — | US | disclosed |
| WO-2024215802-A1 | BENZOFURANYL AND BENZOTHIENYL COMPOUNDS AS P53 MODULATORS | NESTED THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| EP-0945445-B9 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | US | disclosed |
| EP-0945445-B1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| EP-1244616-A1 | (HETERO)BICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SmithKline Beecham plc (GB) | 2002-10-02 | — | — | EP | disclosed |
| US-6344452-B1 | GASTRIN RECEPTOR ANTAGONIST, GASTROINTESTINAL DISORDERS, ETC | ZERIA PHARMACEUTICALS CO., LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| WO-2001047874-A1 | (HETERO)BICYCLYMETHANESULFONYLAMINO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-1085014-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | Zeria Pharmaceutical Co., Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427346-B2 | P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same | SQSTM1, ATG7, BECN1 | CTSK 1671/4885CTSS 908/4885PPARA 385/4885 |
| US-12178842-B2 | PCSK9 antagonist compounds | PCSK9, PCSK7, PCSK6 | CTSK 193/4885CTSS 287/4885PPARA 1100/4885 |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | CD40, CD22, CD2 | CTSK 1217/4885CTSS 561/4885PPARA 3785/4885 |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | CTSK 1531/4885CTSS 764/4885PPARA 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.